82 related articles for article (PubMed ID: 18528286)
21. FGFR3 overexpression is prognostic of adverse outcome for muscle-invasive bladder carcinoma treated with adjuvant chemotherapy.
Sung JY; Sun JM; Chang Jeong B; Il Seo S; Soo Jeon S; Moo Lee H; Yong Choi H; Young Kang S; Choi YL; Young Kwon G
Urol Oncol; 2014 Jan; 32(1):49.e23-31. PubMed ID: 24360661
[TBL] [Abstract][Full Text] [Related]
22. CHIR-258 is efficacious in a newly developed fibroblast growth factor receptor 3-expressing orthotopic multiple myeloma model in mice.
Xin X; Abrams TJ; Hollenbach PW; Rendahl KG; Tang Y; Oei YA; Embry MG; Swinarski DE; Garrett EN; Pryer NK; Trudel S; Jallal B; Mendel DB; Heise CC
Clin Cancer Res; 2006 Aug; 12(16):4908-15. PubMed ID: 16914579
[TBL] [Abstract][Full Text] [Related]
23. Targeting FGFR3 in multiple myeloma: inhibition of t(4;14)-positive cells by SU5402 and PD173074.
Grand EK; Chase AJ; Heath C; Rahemtulla A; Cross NC
Leukemia; 2004 May; 18(5):962-6. PubMed ID: 15029211
[TBL] [Abstract][Full Text] [Related]
24. Fibroblast growth factor receptor 3 protein expression in urothelial carcinoma of the urinary bladder, exhibiting no association with low-grade and/or non-invasive lesions.
Matsumoto M; Ohtsuki Y; Ochii K; Seike Y; Iseda N; Sasaki T; Okada Y; Kurabayashi A; Furihata M
Oncol Rep; 2004 Nov; 12(5):967-71. PubMed ID: 15492779
[TBL] [Abstract][Full Text] [Related]
25. Fibroblast growth factor receptor-3 in urothelial tumorigenesis.
Iyer G; Milowsky MI
Urol Oncol; 2013 Apr; 31(3):303-11. PubMed ID: 22285006
[TBL] [Abstract][Full Text] [Related]
26. Constitutively active FGFR3 with Lys650Glu mutation enhances bortezomib sensitivity in plasma cell malignancy.
Otsuka M; Mizuki M; Fujita J; Kang S; Kanakura Y
Anticancer Res; 2011 Jan; 31(1):113-22. PubMed ID: 21273588
[TBL] [Abstract][Full Text] [Related]
27. Fibroblast growth factor receptor (FGFR) gene amplifications are rare events in bladder cancer.
Fischbach A; Rogler A; Erber R; Stoehr R; Poulsom R; Heidenreich A; Schneevoigt BS; Hauke S; Hartmann A; Knuechel R; Veeck J; Gaisa NT
Histopathology; 2015 Apr; 66(5):639-49. PubMed ID: 24898159
[TBL] [Abstract][Full Text] [Related]
28. Strong FGFR3 staining is a marker for FGFR3 fusions in diffuse gliomas.
Granberg KJ; Annala M; Lehtinen B; Kesseli J; Haapasalo J; Ruusuvuori P; Yli-Harja O; Visakorpi T; Haapasalo H; Nykter M; Zhang W
Neuro Oncol; 2017 Sep; 19(9):1206-1216. PubMed ID: 28379477
[TBL] [Abstract][Full Text] [Related]
29. The inhibitory anti-FGFR3 antibody, PRO-001, is cytotoxic to t(4;14) multiple myeloma cells.
Trudel S; Stewart AK; Rom E; Wei E; Li ZH; Kotzer S; Chumakov I; Singer Y; Chang H; Liang SB; Yayon A
Blood; 2006 May; 107(10):4039-46. PubMed ID: 16467200
[TBL] [Abstract][Full Text] [Related]
30. Immunohistochemical analysis of p53 expression in malignant lymphomas.
Said JW; Barrera R; Shintaku IP; Nakamura H; Koeffler HP
Am J Pathol; 1992 Dec; 141(6):1343-8. PubMed ID: 1466398
[TBL] [Abstract][Full Text] [Related]
31. FGFR3 mutations and a normal CK20 staining pattern define low-grade noninvasive urothelial bladder tumours.
van Oers JM; Wild PJ; Burger M; Denzinger S; Stoehr R; Rosskopf E; Hofstaedter F; Steyerberg EW; Klinkhammer-Schalke M; Zwarthoff EC; van der Kwast TH; Hartmann A
Eur Urol; 2007 Sep; 52(3):760-8. PubMed ID: 17240035
[TBL] [Abstract][Full Text] [Related]
32. Expression of Grb2 distinguishes classical Hodgkin lymphomas from primary mediastinal B-cell lymphomas and other diffuse large B-cell lymphomas.
Miles RR; Mankey CC; Seiler CE; Smith LB; Teruya-Feldstein J; Hsi ED; Elenitoba-Johnson KS; Lim MS
Hum Pathol; 2009 Dec; 40(12):1731-7. PubMed ID: 19716163
[TBL] [Abstract][Full Text] [Related]
33. Fibroblast growth factor receptor 3 is overexpressed in urinary tract carcinomas and modulates the neoplastic cell growth.
Gómez-Román JJ; Saenz P; Molina M; Cuevas González J; Escuredo K; Santa Cruz S; Junquera C; Simón L; Martínez A; Gutiérrez Baños JL; López-Brea M; Esparza C; Val-Bernal JF
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):459-65. PubMed ID: 15701828
[TBL] [Abstract][Full Text] [Related]
34. [Molecular abnormalities in lymphomas].
Delsol G
Bull Cancer; 2010 Nov; 97(11):1347-64. PubMed ID: 21084243
[TBL] [Abstract][Full Text] [Related]
35. Morphoproteomics identifies constitutive activation of the mTORC2/Akt and NF-κB pathways and expressions of IGF-1R, Sirt1, COX-2, and FASN in peripheral T-cell lymphomas: pathogenetic implications and therapeutic options.
Quesada AE; Nguyen ND; Rios A; Brown RE
Int J Clin Exp Pathol; 2014; 7(12):8732-9. PubMed ID: 25674239
[TBL] [Abstract][Full Text] [Related]
36. Intracellular TCR-signaling pathway: novel markers for lymphoma diagnosis and potential therapeutic targets.
Agostinelli C; Rizvi H; Paterson J; Shende V; Akarca AU; Agostini E; Fuligni F; Righi S; Spagnolo S; Piccaluga PP; Clark EA; Pileri SA; Marafioti T
Am J Surg Pathol; 2014 Oct; 38(10):1349-59. PubMed ID: 25118816
[TBL] [Abstract][Full Text] [Related]
37. Molecular grading of urothelial cell carcinoma with fibroblast growth factor receptor 3 and MIB-1 is superior to pathologic grade for the prediction of clinical outcome.
van Rhijn BW; Vis AN; van der Kwast TH; Kirkels WJ; Radvanyi F; Ooms EC; Chopin DK; Boevé ER; Jöbsis AC; Zwarthoff EC
J Clin Oncol; 2003 May; 21(10):1912-21. PubMed ID: 12743143
[TBL] [Abstract][Full Text] [Related]
38. Alternative splicing of fibroblast growth factor receptor 3 produces a secreted isoform that inhibits fibroblast growth factor-induced proliferation and is repressed in urothelial carcinoma cell lines.
Tomlinson DC; L'Hôte CG; Kennedy W; Pitt E; Knowles MA
Cancer Res; 2005 Nov; 65(22):10441-9. PubMed ID: 16288035
[TBL] [Abstract][Full Text] [Related]
39. The differential expression of LCK and BAFF-receptor and their role in apoptosis in human lymphomas.
Paterson JC; Tedoldi S; Craxton A; Jones M; Hansmann ML; Collins G; Roberton H; Natkunam Y; Pileri S; Campo E; Clark EA; Mason DY; Marafioti T
Haematologica; 2006 Jun; 91(6):772-80. PubMed ID: 16769579
[TBL] [Abstract][Full Text] [Related]
40. FGFR3 is overexpressed waldenstrom macroglobulinemia and its inhibition by Dovitinib induces apoptosis and overcomes stroma-induced proliferation.
Azab AK; Azab F; Quang P; Maiso P; Sacco A; Ngo HT; Liu Y; Zhang Y; Morgan BL; Roccaro AM; Ghobrial IM
Clin Cancer Res; 2011 Jul; 17(13):4389-99. PubMed ID: 21521775
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
